← Compound index
COMPOUND RECORD / PIELOTAX

PielotaxПиелотакс

A peptide mixture from calf or pig kidneys, studied in a Russian report on kidney laboratory measures.

Source linked

What the studies found

Comparison in people · 2011

Pielotax: clinical report on a tissue-derived preparation

Blood urate in men
0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care.
Blood urate in women
0.37 ± 0.03 mmol/L with Pielotax versus 0.48 ± 0.02 mmol/L with conventional care.
Residual nitrogen
27.1 ± 0.4 mmol/L with Pielotax versus 30.5 ± 0.6 mmol/L with conventional care.The table marks p < 0.05 versus conventional care.

After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model Gouty nephropathy: 27 treated, 15 controls.

Design 42 participants with gouty nephropathy: 27 received one to two Pielotax capsules three times daily before meals for 30 days alongside conventional therapy, and 15 received conventional therapy. The report describes random assignment without explaining how it was performed.

Important limitations

  • Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.
  • The report measured short-term laboratory markers and gives no detailed adverse-event assessment.

Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Source for the reported results ↗

Study results and tables ↗

Animal research · 2015

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Findings for this preparation

Glomerular filtration was 433.3 µL/min with the kidney complex versus 240.8 with cisplatin alone.

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.

Design Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.

Important limitations

  • Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured. Each outcome applies to the specific arm and preparation tested.

Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176. · Publication record

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Pielotax

Identity / background source ↗

Organ-derived peptide research: clinical findings and lineage ↗

Research background

Pielotax is a kidney-derived peptide complex. A clinical report measured renal markers in gouty nephropathy, and an animal study assessed renal function after cisplatin injury.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
St. Petersburg Institute of Bioregulation and Gerontology · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Gouty nephropathy: 27 treated, 15 controls.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

PEPTIDE RESEARCH / OCT 2026

Related preparations and evidence

Evidence belongs to the preparation actually studied. A tissue extract and a synthetic peptide can belong to the same research tradition without having equivalent effects or safety.

Kidney: the molecular link

Nephropept / separately formulated Pielotax → AED, EDL and AEDG are related experimental sequences

A common tissue target does not establish identical extracts or prove that these sequences were isolated from Nephropept.

Clinical evidence and limitations

Pielotax has a historical institute report. The Nephropept Phase II registry reproduction lists a planned 210-person CKD study without numerical outcomes.

The source leaves the protocol, actual enrollment, clinical results and preparation characteristics uncertain.

Related preparations

Some references concern related extracts, reviews or molecular identification rather than direct studies of this compound.

Explore the full bioregulator collection ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Animal research · 2015

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Glomerular filtration was 433.3 µL/min with the kidney complex versus 240.8 with cisplatin alone.

Study notes and original source
2015Animal / experimentalFull text available

Pielotax kidney peptide complex and three short peptides in cisplatin-treated rats

Author affiliations · St. Petersburg Institute of Bioregulation and Gerontology

Injected kidney polypeptide complex, identified as Pielotax in the Russian reproduction. EDL, AED and AEDG were separate short-peptide arms.

I. I. Zamorskii, T. S. Shchudrova, N. S. Lin’kova, T. E. Nichik, V. Kh. Khavinson · Bulletin of Experimental Biology and Medicine. 2015;159(6):736–739. PMID 26515176.

Filtration rates were 433.3 with the kidney complex, 543.9 with EDL, 305.1 with AED and 469.9 with AEDG versus 240.8 µL/min with cisplatin alone. AED did not significantly improve filtration.

Results and tables

Reported findings and study design

Cisplatin-associated kidney injury with intact and injury controls. Urine was collected over two hours, 72 hours after cisplatin.

Population or model 42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.

Dose, route and schedule

Interventions were intraperitoneal once daily for four days before and three after cisplatin. Kidney complex 300 µg/kg, EDL 3 µg/kg, AED 3 µg/kg, AEDG 7 µg/kg. Cisplatin was a 6 mg/kg intraperitoneal injection 72 hours before sampling.

Protocol source ↗ · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.

Results · Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
MeasureResultComparison, timing and statistics
Glomerular filtration rate433.3 kidney complex, 543.9 EDL, 305.1 AED, 469.9 AEDG vs 240.8 µL/min with cisplatin alone
Plasma creatinine67.43 with kidney complex vs 94.91 µmol/L with cisplatin alonep≤0.05
Diuresis over two hours2.62 kidney complex, 3.02 EDL, 1.81 AED, 2.89 AEDG vs 1.50 mL with cisplatin alone
Selected Table 1 values
Selected Table 1 values
OutcomeIntactCisplatinKidney complexEDLAEDAEDG
Filtration, µL/min502.90240.8433.3543.9305.1469.9
Creatinine, µmol/L64.9094.9167.4368.9582.6077.54
Urine over two hours, mL4.121.502.623.021.812.89

Source for these results ↗ · Reviewed 2026-11-14

Population / setting
42 rats randomized to six equal groups of seven: intact control, cisplatin alone, or cisplatin with kidney complex, EDL, AED or AEDG.
Source reviewed
Original journal full text and Table 1. Russian reproduction identifies the branded kidney complex.
Study limitations
  • Small rat arms and a pretreatment design. Clinical outcomes and the effects of marketed oral products were not measured.
  • Each outcome applies to the specific arm and preparation tested.

Reviewed 2026-11-14.

Read the source ↗

Comparison in people · 2011

Pielotax: clinical report on a tissue-derived preparation

After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.

Blood urate in men · 0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care.

Study notes and original source
2011Human comparative studyFull text available

Pielotax: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2011 study/report date, not website publication date

After 30 days, blood urate was 0.44 versus 0.56 mmol/L in men and 0.37 versus 0.48 mmol/L in women, comparing adjunctive Pielotax with conventional treatment.

Results and tables

Reported findings and study design

42 participants with gouty nephropathy: 27 received one to two Pielotax capsules three times daily before meals for 30 days alongside conventional therapy, and 15 received conventional therapy. The report describes random assignment without explaining how it was performed.

Population or model Gouty nephropathy: 27 treated, 15 controls.

Results · Medical Center report, PDF pages 44–45, Tables 1–2
MeasureResultComparison, timing and statistics
Blood urate in men0.44 ± 0.02 mmol/L with Pielotax versus 0.56 ± 0.01 mmol/L with conventional care.
Blood urate in women0.37 ± 0.03 mmol/L with Pielotax versus 0.48 ± 0.02 mmol/L with conventional care.
Residual nitrogen27.1 ± 0.4 mmol/L with Pielotax versus 30.5 ± 0.6 mmol/L with conventional care.The table marks p < 0.05 versus conventional care.

The report measured short-term laboratory markers and gives no detailed adverse-event assessment.

Source for these results ↗ · Reviewed 2026-11-16

Population / setting
Gouty nephropathy: 27 treated, 15 controls.
Source reviewed
English compilation, PDF pages 43 onward; selected report text/tables checked. Russian original not reconciled.
Study limitations
  • Sequence generation, concealment and long-term outcomes remain unresolved. Laboratory-marker changes do not establish prevention of kidney failure.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-11-16.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗